The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
Abstract
Background— Although randomized trials of cyclooxygenase-2 (COX-2) inhibitors have shown increased cardiovascular risk, studies of nonselective, nonsteroidal antiinflammatory drugs (NSAIDs) and acetaminophen have been inconsistent. Methods and Results— We examined the influence of NSAIDs and acetaminophen on the risk of major cardiovascular events (nonfatal myocardial infarction, fatal coronary heart disease, nonfatal and fatal stroke) in a prospective cohort of 70 971 women, aged 44 to 69 years at baseline, free of known cardiovascular disease or cancer, who provided medication data biennially since 1990. During 12 years of follow-up, we confirmed 2041 major cardiovascular events. Women who reported occasional (1 to 21 d/mo) use of NSAIDs or acetaminophen did not experience a significant increase in the risk of cardiovascular events. However, after adjustment for cardiovascular risk factors, women who frequently (≥22 d/mo) used NSAIDs had a relative risk (RR) for a cardiovascular event of 1.44 (95% CI, 1.27 to 1.65) compared with nonusers, whereas those who frequently consumed acetaminophen had a RR of 1.35 (95% CI, 1.14 to 1.59). The elevated risk associated with frequent NSAID use was particularly evident among current smokers (RR=1.82; 95% CI, 1.38 to 2.42) and was absent among never smokers ( P interaction =0.02). Moreover, we observed significant dose-response relations: Compared with nonusers, the RRs for a cardiovascular event among women who used ≥15 tablets per week were 1.86 (95% CI, 1.27 to 2.73) for NSAIDs and 1.68 (95% CI, 1.10 to 2.58) for acetaminophen. Conclusions— Use of NSAIDs or acetaminophen at high frequency or dose is associated with a significantly increased risk for major cardiovascular events, although more moderate use did not confer substantial risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sudbø, J., Lee, J., Lippman, S., Mork, J., Sagen, S., Flatner, N., Ristimaki, A. P., Sudbø, A., Mao, L., Zhou, X. K., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67488-0 · Cited by 78
RetractedChronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Reproducibility and validity of a semiquantitative food frequency questionnaire
WILLETT, W. C., SAMPSON, L., STAMPFER, M. J., ROSNER, B., BAIN, C., WITSCHI, J., HENNEKENS, C. H., & SPEIZER, F. E. (1985) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114086 · Cited by 4,274
Self-citationCardiovascular Survey Methods.
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-69-6-1335_2 · Cited by 3,052
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
Self-citationMcAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,218
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
TEST OF THE NATIONAL DEATH INDEX
STAMPFER, M. J., WILLETT, W. C., SPEIZER, F. E., DYSERT, D. C., LIPNICK, R., ROSNER, B., & HENNEKENS, C. H. (1984) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113804 · Cited by 790
Self-citationDo Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis
Johnson, A. G., Nguyen, T. V., & Day, R. O. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-4-199408150-00011 · Cited by 717
Hippisley-Cox, J., & Coupland, C. (2005) · BMJ · doi:10.1136/bmj.330.7504.1366 · Cited by 561
Perneger, T. V., Whelton, P. K., & Klag, M. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412223312502 · Cited by 484
Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer
Chan, A. T. (2005) · JAMA · doi:10.1001/jama.294.8.914 · Cited by 478
Self-citationMamdani, M., Juurlink, D. N., Lee, D. S., Rochon, P. A., Kopp, A., Naglie, G., Austin, P. C., Laupacis, A., & Stukel, T. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16299-5 · Cited by 435
Effect of ibuprofen on cardioprotective effect of aspirin
MacDonald, T., & Wei, L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12509-3 · Cited by 419
Ray, W. A., Stein, C. M., Hall, K., Daugherty, J. R., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07370-1 · Cited by 326
Johnsen, S. P. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.9.978 · Cited by 288
Mamdani, M., Rochon, P., Juurlink, D. N., Anderson, G. M., Kopp, A., Naglie, G., Austin, P. C., & Laupacis, A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.481 · Cited by 281
A Prospective Study of Aspirin Use and Primary Prevention of Cardiovascular Disease in Women
Manson, J. E. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470040085027 · Cited by 272
Self-citationKurth, T., Glynn, R. J., Walker, A. M., Chan, K. A., Buring, J. E., Hennekens, C. H., & Gaziano, J. M. (2003) · Circulation · doi:10.1161/01.cir.0000087593.07533.9b · Cited by 254
Lévesque, L. E., Brophy, J. M., & Zhang, B. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00113 · Cited by 249
COX-2 Inhibitors — Lessons in Drug Safety
Psaty, B. M., & Furberg, C. D. (2005) · New England Journal of Medicine · doi:10.1056/nejme058042 · Cited by 241
Watson, D. J., Rhodes, T., Cai, B., & Guess, H. A. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1105 · Cited by 238
Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction
Solomon, D. H., Glynn, R. J., Levin, R., & Avorn, J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1099 · Cited by 234
Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population
García Rodríguez, L. A., Varas-Lorenzo, C., Maguire, A., & González-Pérez, A. (2004) · Circulation · doi:10.1161/01.cir.0000132491.96623.04 · Cited by 221
Association Between Naproxen Use and Protection Against Acute Myocardial Infarction
Rahme, E., Pilote, L., & LeLorier, J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1111 · Cited by 203
Non-Narcotic Analgesic Dose and Risk of Incident Hypertension in US Women
Forman, J. P., Stampfer, M. J., & Curhan, G. C. (2005) · Hypertension · doi:10.1161/01.hyp.0000177437.07240.70 · Cited by 196
Self-citationFrequency of Analgesic Use and Risk of Hypertension in Younger Women
Curhan, G. C., Willett, W. C., Rosner, B., & Stampfer, M. J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.19.2204 · Cited by 179
Self-citationGarcía Rodríguez, L. A., Varas, C., & Patrono, C. (2000) · Epidemiology · doi:10.1097/00001648-200007000-00004 · Cited by 177
Lifetime Nonnarcotic Analgesic Use and Decline in Renal Function in Women
Curhan, G. C., Knight, E. L., Rosner, B., Hankinson, S. E., & Stampfer, M. J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.14.1519 · Cited by 166
Self-citationHudson, M., Richard, H., & Pilote, L. (2005) · BMJ · doi:10.1136/bmj.330.7504.1370 · Cited by 164
Nonnarcotic Analgesic Use and the Risk of Hypertension in US Women
Dedier, J., Stampfer, M. J., Hankinson, S. E., Willett, W. C., Speizer, F. E., & Curhan, G. C. (2002) · Hypertension · doi:10.1161/01.hyp.0000035856.77718.da · Cited by 145
Self-citationGlutathione reverses endothelial dysfunction and improves nitric oxide bioavailability
Prasad, A., Andrews, N. P., Padder, F. A., Husain, M., & Quyyumi, A. A. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00216-8 · Cited by 133
Kimmel, S. E., Berlin, J. A., Reilly, M. P., Jaskowiak, J., Kishel, L., Chittams, J. L., & Strom, B. L. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.08.064 · Cited by 123
An Epidemiologic Study of Abuse of Analgesic Drugs
Dubach, U. C., ROSNER, B. A., & Stürmer, T. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101173240304 · Cited by 123
Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk
Howard, P. A., & Delafontaine, P. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.09.043 · Cited by 118
Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol)
Grèen, K., Drvota, V., & Vesterqvist, O. (1989) · Prostaglandins · doi:10.1016/0090-6980(89)90001-4 · Cited by 112
Prospective Study of Aspirin Use and Risk of Stroke in Women
Iso, H., Hennekens, C. H., Stampfer, M. J., Rexrode, K. M., Colditz, G. A., Speizer, F. E., Willett, W. C., & Manson, J. E. (1999) · Stroke · doi:10.1161/01.str.30.9.1764 · Cited by 95
Self-citationRenal Function and Risk of Myocardial Infarction in an Elderly Population: The Rotterdam Study
Brugts, J. J., Knetsch, A. M., Mattace-Raso, F. U. S., Albert Hofman, D., & Witteman, J. C. M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.22.2659 · Cited by 90
Chalmers, J. P., West, M., Wing, L. M. H., Bune, A. J. C., & Graham, J. R. (1984) · Clinical and Experimental Hypertension · doi:10.3109/10641968409039582 · Cited by 88
Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs
Bak, S., Andersen, M. T., Tsiropoulos, I., Rodríguez, L. A. G., Hallas, J., Christensen, K., & Gaist, D. (2003) · Stroke · doi:10.1161/01.str.0000053029.45352.a0 · Cited by 87
Fischer, L., Schlienger, R. G., Matter, C. M., Jick, H., & Meier, C. R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.22.2472 · Cited by 86
The Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
BENNETT, J. S., Daugherty, A., Herrington, D. M., Greenland, P., Roberts, H. R., & Taubert, K. A. (2005) · Circulation · doi:10.1161/01.cir.0000160005.90598.41 · Cited by 84
Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study
Curtis, J. P., Wang, Y., Portnay, E. L., et al. (2003) · BMJ · doi:10.1136/bmj.327.7427.1322 · Cited by 83
Use of nonsteroidal anti‐inflammatory drugs and the risk of first‐time acute myocardial infarction
Schlienger, R. G., Jick, H., & Meier, C. R. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01637.x · Cited by 75
Johnsen, S. P., Pedersen, L. H., Friis, S., Blot, W. J., McLaughlin, J. K., Olsen, J. H., & Sørensen, H. T. (2003) · Stroke · doi:10.1161/01.str.0000054057.11892.5b · Cited by 61
Jick, S. S. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.9.741.35209 · Cited by 42
Liesener, S. (2000) · Platelets · doi:10.1080/095371000403125 · Cited by 41
Nonnarcotic Analgesic Use and the Risk of Hypertension in US Women
Egan, B. M. (2002) · Hypertension · doi:10.1161/01.hyp.0000035857.73890.67 · Cited by 10
Nonnarcotic analgesic use and the risk of hypertension.
O’Brien, B. (2003) · Europe PMC (PubMed Central) · Cited by 3
Cited by
CURCUMIN: THE INDIAN SOLID GOLD
Aggarwal, B. B., Sundaram, C., Malani, N., & Ichikawa, H. (2007) · ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY · doi:10.1007/978-0-387-46401-5_1 · Cited by 1,647
Primary Prevention of Colorectal Cancer
Chan, A. T., & Giovannucci, E. L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.057 · Cited by 723
Self-citationBruyère, O., Honvo, G., Veronese, N., Arden, N. K., Branco, J., Curtis, E. M., Al-Daghri, N. M., Herrero-Beaumont, G., Martel-Pelletier, J., Pelletier, J.-P., et al. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.04.008 · Cited by 695
Sostres, C., Gargallo, C. J., Arroyo, M. T., & Lanas, A. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2009.11.005 · Cited by 685
Graham, G. G., Davies, M. J., Day, R. O., Mohamudally, A., & Scott, K. F. (2013) · Inflammopharmacology · doi:10.1007/s10787-013-0172-x · Cited by 671
Metadata
- Authors
- Chan, A. T., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M., Curhan, G. C., Rimm, E. B., Willett, W. C., & Fuchs, C. S.
- Venue
- Circulation
- Published
- 2006-03-28
- Volume
- 113
- Issue
- 12
- Pages
- 1578-1587
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2020036206
- Cited by
- 319
- References
- 55
- FWCI
- 17.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.